RxDoctor Payments Data

Steve Hwang, DO

Family Medicine · Sacramento, CANPI 1902812837

Payments from drug & device makers

$9,590in general payments, 2019–2025

Across 527 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$896
  • Pfizer$814
  • Novo Nordisk$699
  • AstraZeneca$699
  • Boehringer Ingelheim$686
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$9,33597%
  • Education$2553%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,590 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$82,153
Medicare patients
130
Services billed
1,645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide94$105,761
FarxigaDapagliflozin Propanediol46$64,226
JardianceEmpagliflozin22$32,459
EliquisApixaban28$30,575
JanuviaSitagliptin Phosphate24$29,452
XareltoRivaroxaban14$22,809
TrulicityDulaglutide24$22,564
ViberziEluxadoline11$17,129
MyrbetriqMirabegron11$14,146
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen290$8,481
Lantus SolostarInsulin Glargine,hum.Rec.Anlog47$8,439
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,920
Atorvastatin Calcium420$6,414
Gabapentin118$3,411
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide120$2,440

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$699$105,76194 claims
AstraZenecaFarxiga, Breztri Aerosphere$699$72,14658 claims
Boehringer IngelheimJardiance$686$32,45922 claims
PfizerEliquis$814$30,57528 claims
MerckJanuvia$353$29,45224 claims
Johnson & JohnsonXarelto$679$22,80914 claims
Lilly USA, LLCTrulicity$896$22,56424 claims
AbbVieViberzi, Synthroid$1,332$18,45124 claims
Astellas Pharma US IncMyrbetriq$423$14,14611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →